Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium phosphate, dibasic + sodium phosphate, monobasic (Hospira, Inc.)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Sodium Phosphates Injection is a sterile, concentrated intravenous solution containing a combination of sodium phosphate, dibasic, anhydrous and sodium phosphate, monobasic, monohydrate. Developed by Hospira (now a Pfizer company) and approved under NDA 018892, it functions as an inorganic electrolyte replenisher. The drug is primarily indicated for the prevention and treatment of hypophosphatemia in patients with restricted or no oral intake, as well as an additive for preparing specific parenteral fluid formulas. By restoring inorganic phosphate levels, it facilitates the synthesis of essential high-energy phosphates such as adenosine triphosphate (ATP) and 2,3-diphosphoglycerate (DPG), which are vital for cellular energy metabolism and erythrocyte function.
- Brand names
- Sodium Phosphates
- Other names
- Sodium Phosphates Injection, USP
02
Targets
Intestinal luminal osmolarity
Beyond the preview
Go deeper on sodium phosphate, dibasic + sodium phosphate, monobasic (Hospira, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium phosphate, dibasic + sodium phosphate, monobasic (Hospira, Inc.).